Hypertension
Conditions
Interventions
Nighttime-blood pressure was measured using the home blood pressure device (HEM-7252G-HP
Omron, Kyoto, Japan) at 2:00, 3:00, 4:00, and 5 AM (4 points) for consecutive 7 days (at leaset more than 5 days). Nocturnal hypertension was defined as the average of all systolic blood pressure read
or=120 mmHg. All patients with nocturnal hypertension receive aggressive antihypertensive therapy for 6 month to achieve target nighttime-home systolic blood pressure <
120 mmHg. During treatment, nignttime-home blood pressure was measured at 2 month and 6 month just before hospital visiting for 5-7 days. If the nighttime-blood pressure was not normalized at 2 month,
Sponsors
Department of Cardiovascular Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patietns with hypertension defined in the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014) as a clinic systolic blood pressure of 140 mmHg or more and/or a diastolic blood pressure of 90 mmHg or more, or a home systolic blood pressure of 135 mmHg or more and/or a diastolic blood pressure of 85 mmHg or more who have been receiving antihypertensive therapy for more than 3 months. (2)Patients who can be followed up for 5 years (3)Patients who have given written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: (1)Patients with severe valvular heart disease (2)Patients with moderate or severe cardiac dysfunction (NYHA class III or IV) (3)Patients with lethal arrhythmia after receiving implantable cardioverter defibrillator (4)Patients with end-stage renal disease receiving dialysis (5)Patients with malignant disease (6)Patients receiving corticosteroid or immunosuppressive agent (7)Patients with hepatic cirrhosis (8)Pregnant, possible pregnant, or lactating women (9)Patients who are considered not eligible for the study by the attending doctor due to other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) Proportion of patients whose elevated nighttime-systolic blood pressure (>or=120 mmHg) was reduced within the normal range (<120 mmHg) after 6-month agressive antihypertensive therapy. (2)Effective combination, dose, and dosing time of antihypertensive agents. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)All fatal or nonfatal cardiovascular events (cerebravascular disease, coronary heart disease, death due to heart failure, and sudden death) (2)New onset of left ventricular hypertrophy and atrial fibrillation (3)New onset of diabetes mellitus (4)New onset of proteinuria and impairement of kidney function (5)Change of endothleial function assessed by flow-mediated vasodilation (6)Adverse events | — |
Countries
Japan
Contacts
Public ContactTatsuya Maruhashi
Hiroshima University Department of Regeneration and Medicine, Research Center for Radiation Genome Medicine, Research Ins
Outcome results
None listed